Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.本文提供結合MET的抗體以及雙特異性抗原結合分子及其使用方法。該雙特異性抗原結合分子包含第一抗原結合域以及第二抗原結合域，其中該第一抗原結合域及第二抗原結合域結合至人類MET之胞外域的兩個不同(較佳非重疊)表位。該等雙特異性抗原結合分子能夠阻斷人類MET及其配體HGF之間的交互作用。該等雙特異性抗原結合分子可表現出最小或無MET促效劑活性，例如與僅包含雙特異性分子之一個抗原結合域的單價抗原結合分子相較，該等單價抗原結合分子傾向展現出不樂見的MET促效劑活性。亦包括含有本文提供之抗體或雙特異性抗原結合分子結合至細胞毒性劑、放射性核種或其他部分的抗體-藥物接合物(ADC)，以及透過向個體投與雙特異性抗原結合分子或其ADC來治療個體之癌症的方法。
